Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Capital Leases: 2014-2025

Historic Capital Leases for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Sep 2025 value amounting to $40,000.

  • Lineage Cell Therapeutics' Capital Leases fell 50.00% to $40,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $40,000, marking a year-over-year decrease of 50.00%. This contributed to the annual value of $67,000 for FY2024, which is 26.37% down from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Capital Leases stood at $40,000 for Q3 2025, which was down 16.67% from $48,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Capital Leases' 5-year high stood at $133,000 during Q1 2023, with a 5-year trough of $12,000 in Q3 2021.
  • Its 3-year average for Capital Leases is $78,818, with a median of $79,000 in 2024.
  • As far as peak fluctuations go, Lineage Cell Therapeutics' Capital Leases tumbled by 74.19% in 2021, and later surged by 506.25% in 2023.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Capital Leases stood at $30,000 in 2021, then spiked by 180.00% to $84,000 in 2022, then grew by 8.33% to $91,000 in 2023, then declined by 26.37% to $67,000 in 2024, then plummeted by 50.00% to $40,000 in 2025.
  • Its last three reported values are $40,000 in Q3 2025, $48,000 for Q2 2025, and $51,000 during Q1 2025.